top of page

Developing Salivary Components as Therapeutics for Oral Health (R21 Clinical Trial Not Allowed)

HHS-NIH11

Status:

Active

August 29, 2023

Posted:

Deadline: 

November 22, 2023

Funding

Program:

Award Floor:

Ceiling:

275000

Match Required?

No

Eligibility

All

States:

Entity Types:

State governments, County governments, City or township governments, Special district governments, Independent school districts, Public & State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities, Native American tribal organizations, Nonprofits (with 501(c)(3) status), Nonprofits (without 501(c)(3) status)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Contact

Email:

Phone:

Source Type:

Federal

This FOA will encourage interdisciplinary research that harnesses the functional components of saliva towards therapeutics. It is expected that outcomes will facilitate development of highly effective surrogate saliva for clinical applications. Recent developments in salivary gland transcriptomics and its integrations with saliva and blood plasma components have enabled linkage of human salivary proteins to the salivary gland where they are generated, identification of salivary-gland-specific genes, uncovering gene repertoires allowing examinations of salivary components in a context-specific manner. It is well-recognized that the context of use of saliva highly determines the components in the saliva that need to be replenished. This funding opportunity aims to establish a better understanding of these contexts and components, thus laying the groundwork for new therapies and technologies.

Applications responsive to this funding opportunity should address unmet clinical therapeutic needs in areas of dry mouth, dental materials, remineralization, oral immunology, and cellular therapies that recapitulate properties of human saliva containing antimicrobial components and incorporating its immunomodulatory and remineralization properties. Studies are expected to lead to the development of novel therapies to modulate imbalances in the composition and quantity of saliva at the individual’s level resulting from injury, illness, or individual deficiencies and to enhance growth and repair of oral tissues to promote and restore oral health.

Tired of searching for grants? Consider a Scouting Report.

bottom of page